Loading
CEPHEUS extended the quadruplet advantage to patients who do not have a transplant.
CEPHEUS, trial NCT03652064 sponsored by Janssen and reported in 2024, extended the quadruplet advantage to newly diagnosed myeloma patients who do not have a transplant, adding daratumumab to bortezomib, lenalidomide and dexamethasone. It randomised 395 transplant-ineligible or transplant-deferred patients and met its primary endpoint of MRD negativity, with a clear progression-free survival benefit at 54 months, and it was approved in 2025 alongside IMROZ-era labelling. OnCo links it to multiple myeloma, daratumumab, bortezomib, lenalidomide, the quadruplet pairing and the CEPHEUS paper. It is notable for using MRD negativity as its main endpoint, and whether regulators accept that surrogate more widely is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CD38 antibody added to PI-IMiD-dex (quadruplet induction), CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint, Newly diagnosed multiple myeloma, transplant-ineligible, Bortezomib.
Shares CD38 antibody added to PI-IMiD-dex (quadruplet induction), CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint, Newly diagnosed multiple myeloma, transplant-ineligible, Daratumumab.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Daratumumab, Lenalidomide, Johnson & Johnson.
Shares Daratumumab, Bortezomib, Lenalidomide, Johnson & Johnson.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Daratumumab, Bortezomib, Lenalidomide.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Daratumumab, Lenalidomide, Johnson & Johnson.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Daratumumab, Lenalidomide, Monoclonal antibodies.
Shares Daratumumab, Bortezomib, Lenalidomide, Johnson & Johnson.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/